Multicancer Screening Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs)), By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and Other Technologies), By Sample (Tissue, Blood, Saliva and Buccal Swab, and Others), By Method (DNA, RNA, and Proteins), By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, and Other Cancer Types), By Application (Clinical, Research), By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, and Other End Users), By Region and Competition
Multi-cancer screening market is gaining significant traction across the world. Multi-cancer screening has the potential to find more than one type of cancer from a single sample of blood. Several types of multicancer screening tests that are currently accessible in the world include blood tests, imaging tests, genetic tests, liquid biopsy, stool tests, and others. Among various types of tests, the liquid biopsy test is the most prominent since it can be carried out rapidly, provides genomic, proteomic, and metabolomic information, and is less invasive than tissue biopsies. Breast cancer, lung cancer, colorectal cancer, pancreatic cancer, liver cancer, ovarian cancer, stomach cancer, esophageal cancer, and prostate cancer are some of the cancer types that can be easily detected through multi-cancer screening tests. The increasing prevalence of cancer in various countries of the world especially Australia, New Zealand, Ireland, Hungary, and the United States of America is increasing the demand for multicancer screening tests during the forecast period. Growth in the support provided by the government to improve the quality of medical services provided in every country is also propelling the global multicancer screening market in the forecast period. Moreover, the government is actively participating in taking preventive measures, for controlling the prevalence of cancer in every country by the implementation of new health policies and introduction of healthcare insurance every year. Furthermore, the growth in the geriatric population of the country and the increase in the prevalence of certain types of cancers, which are associated with people, especially during their elder age is also expected to boost the global multicancer screening market in upcoming years.
Increasing Prevalence of Chronic Diseases
Cancer is one of the leading causes of death worldwide, and the incidence of cancer is expected to continue to rise in the coming years due to various factors such as aging populations, changes in lifestyle, and environmental factors. The most common type of cancer prevailing in the regions of developing countries is breast cancer. For instance, in the United States of America, around 3,00,590 new cases of breast cancer were diagnosed of breast cancer in 2023. Another type of cancers, which is emerging in the world followed by breast cancer comprises of lung cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, and cervical cancer. According to the report published by the World Health Organization (WHO) in 2022, around 2.26 million cases of breast cancer were worldwide in 2020, followed by 2.21 million cases of lung cancer, 1.93 million cases of colon and rectum cancer, 1.41 million cases of prostate cancer, 1.20 million cases of skin cancer (non-melanoma) and 1.09 million cases of stomach cancer. The growing prevalence of cancer in the world is resulting in a noticeable rise in the mortality rate of each country with every passing year. As per the report published by World Cancer Research Fund on global cancer rates, it has been concluded that Denmark has recorded the highest cancer rate of 326.1 cases per 1,00,000 population, followed by Ireland with 317 cases, Australia with 314.1 cases, New Zealand with 309.2 cases and Belgium with 306.8 per 1,00,000 population and so on. The growing prevalence of several kinds of cancers is increasing the demand for multicancer screening devices in the world which can detect symptoms of multiple cancer beforehand and can thereby decrease the mortality rate of the world, which is further expected to propel the global multicancer screening market during the forecast period.
Growth in Government Support
The Multicancer screening market refers to the development and sale of tests and services that can detect various types of cancers in individuals. Government support can play a significant role in driving growth in this market. Many governments are investing in research and development of cancer screening tests and technologies. For instance, the National Cancer Institute in the United States provides funding for various multicancer screening trials and studies. They also play a crucial role in shaping policies that incentivize or mandate cancer screening.
Moreover, governing bodies of every country also launch public awareness campaigns to promote cancer screening and early detection. These campaigns focus on educating people about the importance of regular screening for cancer and encourage them to get screened.
Furthermore, governments can collaborate with private companies and organizations to advance cancer screening technologies. In the case of cancer screening programs, Public-private partnerships (PPPs) may be formed to increase awareness and access to screening, reduce costs, and improve the quality of screening services. Development in the support provided by the government to reduce the prevalence of cancer in every country along with the introduction of new health insurance plans every year is expected to register impressive growth in the global multicancer screening market in upcoming years.
Increase in Geriatric Population
With growing age, the risk of developing cancer increases in people, which is fueling the demand for cancer screening tests among the elderly population in the country. Some of the most common types of cancers, which are usually diagnosed in elderly people across the country include pancreatic cancer, skin cancer, bladder cancer, lymphoma, leukemia, prostate cancer, and others. According to the report published by Union for International Cancer Control (UICC) in 2023, it has been observed that around 7.2 million of those above 70 years of age were diagnosed with cancer and approximately 4.4 million of them resulted in death due to cancer. However, growing awareness among geriatric people in passing years to prevent themselves from cancer is expected to register a lucrative growth in the global multicancer screening market during the forecast period.
Market Segmentation
The global multicancer screening market is segmented based on test type, technology, sample, method, cancer type, application, end user, and region. In terms of test type, the multicancer screening market is categorized into laboratory-developed tests (LDTs) and in-vitro diagnostics (IVDs). Based on technology, the global multicancer screening market is fragmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), Immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and other technologies. Based on sample, the multicancer screening market is categorized into tissue, blood, saliva and buccal swab, and others. Based on this method, the market is segmented into DNA, RNA, and proteins. Based on cancer type, the global multicancer screening market is fragmented into breast and gynecologic, gastrointestinal, endocrine, genitourinary, skin, brain/nervous system, sarcoma, hematological malignancies, lung, head and neck, and other cancer types. Based on application, the market is segmented into clinical and research. Based on end user, the market is segmented into hospitals, diagnostic and clinical laboratories, academic research institutions, and other end users.
Market Players
Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock Biotech Limited, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Genecast Biotechnology Co., Ltd., Guardant Health, Inc., Illumina, Inc. (GRAIL, LLC.), and Konica Minolta, Inc. (Ambry Genetics).
Report Scope:
In this report, the global multicancer screening market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the global multicancer screening market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Increasing Prevalence of Chronic Diseases
Cancer is one of the leading causes of death worldwide, and the incidence of cancer is expected to continue to rise in the coming years due to various factors such as aging populations, changes in lifestyle, and environmental factors. The most common type of cancer prevailing in the regions of developing countries is breast cancer. For instance, in the United States of America, around 3,00,590 new cases of breast cancer were diagnosed of breast cancer in 2023. Another type of cancers, which is emerging in the world followed by breast cancer comprises of lung cancer, colorectal cancer, prostate cancer, stomach cancer, liver cancer, and cervical cancer. According to the report published by the World Health Organization (WHO) in 2022, around 2.26 million cases of breast cancer were worldwide in 2020, followed by 2.21 million cases of lung cancer, 1.93 million cases of colon and rectum cancer, 1.41 million cases of prostate cancer, 1.20 million cases of skin cancer (non-melanoma) and 1.09 million cases of stomach cancer. The growing prevalence of cancer in the world is resulting in a noticeable rise in the mortality rate of each country with every passing year. As per the report published by World Cancer Research Fund on global cancer rates, it has been concluded that Denmark has recorded the highest cancer rate of 326.1 cases per 1,00,000 population, followed by Ireland with 317 cases, Australia with 314.1 cases, New Zealand with 309.2 cases and Belgium with 306.8 per 1,00,000 population and so on. The growing prevalence of several kinds of cancers is increasing the demand for multicancer screening devices in the world which can detect symptoms of multiple cancer beforehand and can thereby decrease the mortality rate of the world, which is further expected to propel the global multicancer screening market during the forecast period.
Growth in Government Support
The Multicancer screening market refers to the development and sale of tests and services that can detect various types of cancers in individuals. Government support can play a significant role in driving growth in this market. Many governments are investing in research and development of cancer screening tests and technologies. For instance, the National Cancer Institute in the United States provides funding for various multicancer screening trials and studies. They also play a crucial role in shaping policies that incentivize or mandate cancer screening.
Moreover, governing bodies of every country also launch public awareness campaigns to promote cancer screening and early detection. These campaigns focus on educating people about the importance of regular screening for cancer and encourage them to get screened.
Furthermore, governments can collaborate with private companies and organizations to advance cancer screening technologies. In the case of cancer screening programs, Public-private partnerships (PPPs) may be formed to increase awareness and access to screening, reduce costs, and improve the quality of screening services. Development in the support provided by the government to reduce the prevalence of cancer in every country along with the introduction of new health insurance plans every year is expected to register impressive growth in the global multicancer screening market in upcoming years.
Increase in Geriatric Population
With growing age, the risk of developing cancer increases in people, which is fueling the demand for cancer screening tests among the elderly population in the country. Some of the most common types of cancers, which are usually diagnosed in elderly people across the country include pancreatic cancer, skin cancer, bladder cancer, lymphoma, leukemia, prostate cancer, and others. According to the report published by Union for International Cancer Control (UICC) in 2023, it has been observed that around 7.2 million of those above 70 years of age were diagnosed with cancer and approximately 4.4 million of them resulted in death due to cancer. However, growing awareness among geriatric people in passing years to prevent themselves from cancer is expected to register a lucrative growth in the global multicancer screening market during the forecast period.
Market Segmentation
The global multicancer screening market is segmented based on test type, technology, sample, method, cancer type, application, end user, and region. In terms of test type, the multicancer screening market is categorized into laboratory-developed tests (LDTs) and in-vitro diagnostics (IVDs). Based on technology, the global multicancer screening market is fragmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), Immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH), and other technologies. Based on sample, the multicancer screening market is categorized into tissue, blood, saliva and buccal swab, and others. Based on this method, the market is segmented into DNA, RNA, and proteins. Based on cancer type, the global multicancer screening market is fragmented into breast and gynecologic, gastrointestinal, endocrine, genitourinary, skin, brain/nervous system, sarcoma, hematological malignancies, lung, head and neck, and other cancer types. Based on application, the market is segmented into clinical and research. Based on end user, the market is segmented into hospitals, diagnostic and clinical laboratories, academic research institutions, and other end users.
Market Players
Agilent Technologies, Inc., Atara Biotherapeutics, Inc., Burning Rock Biotech Limited, Exact Sciences Corp., F. Hoffmann-La Roche Ltd., Fulgent Genetics, Inc., Genecast Biotechnology Co., Ltd., Guardant Health, Inc., Illumina, Inc. (GRAIL, LLC.), and Konica Minolta, Inc. (Ambry Genetics).
Report Scope:
In this report, the global multicancer screening market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Multicancer Screening Market, By Test Type:
- Laboratory Developed Tests (LDTs)
- In-Vitro Diagnostics (IVDs)
- Multicancer Screening Market, By Technology:
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Immunohistochemistry (IHC)
- Fluorescence In-Situ Hybridization (FISH)
- Other Technologies
- Multicancer Screening Market, By Sample:
- Tissue
- Blood
- Saliva and Buccal Swab
- Others
- Multicancer Screening Market, By Method:
- DNA
- RNA
- Proteins
- Multicancer Screening Market, By Cancer Type:
- Breast and Gynecologic
- Gastrointestinal
- Endocrine
- Genitourinary
- Skin
- Brain/Nervous System
- Sarcoma
- Hematological Malignancies
- Lung
- Head and Neck
- Other Cancer Types
- Multicancer Screening Market, By Application:
- Clinical
- Research
- Multicancer Screening Market, By End User:
- Hospitals
- Diagnostic and Clinical Laboratories
- Academic Research Institutions
- Other End Users
- Global Multicancer Screening Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the global multicancer screening market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL MULTICANCER SCREENING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs))
5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and Other Technologies)
5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, and Others)
5.2.4. By Method (DNA, RNA, and Proteins)
5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, and Other Cancer Types)
5.2.6. By Application (Clinical, Research)
5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, and Other End Users)
5.2.8. By Region
5.2.9. By Company (2022)
5.3. Product Market Map
6. NORTH AMERICA MULTICANCER SCREENING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value & Volume
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Technology
6.2.3. By Sample
6.2.4. By Method
6.2.5. By Cancer Type
6.2.6. By Application
6.2.7. By End User
6.2.8. By Country
6.3. North America: Country Analysis
6.3.1. United States Multicancer Screening Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value & Volume
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By Technology
6.3.1.2.3. By Sample
6.3.1.2.4. By Method
6.3.1.2.5. By Cancer Type
6.3.1.2.6. By Application
6.3.1.2.7. By End User
6.3.2. Mexico Multicancer Screening Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value & Volume
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type
6.3.2.2.2. By Technology
6.3.2.2.3. By Sample
6.3.2.2.4. By Method
6.3.2.2.5. By Cancer Type
6.3.2.2.6. By Application
6.3.2.2.7. By End User
6.3.3. Canada Multicancer Screening Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value & Volume
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type
6.3.3.2.2. By Technology
6.3.3.2.3. By Sample
6.3.3.2.4. By Method
6.3.3.2.5. By Cancer Type
6.3.3.2.6. By Application
6.3.3.2.7. By End User
7. EUROPE MULTICANCER SCREENING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Technology
7.2.3. By Sample
7.2.4. By Method
7.2.5. By Cancer Type
7.2.6. By Application
7.2.7. By End User
7.2.8. By Country
7.3 Europe: Country Analysis
7.3.1. France Multicancer Screening Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value & Volume
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By Technology
7.3.1.2.3. By Sample
7.3.1.2.4. By Method
7.3.1.2.5. By Cancer Type
7.3.1.2.6. By Application
7.3.1.2.7. By End User
7.3.2. Germany Multicancer Screening Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value & Volume
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type
7.3.2.2.2. By Technology
7.3.2.2.3. By Sample
7.3.2.2.4. By Method
7.3.2.2.5. By Cancer Type
7.3.2.2.6. By Application
7.3.2.2.7. By End User
7.3.3. United Kingdom Multicancer Screening Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value & Volume
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Test Type
7.3.3.2.2. By Technology
7.3.3.2.3. By Sample
7.3.3.2.4. By Method
7.3.3.2.5. By Cancer Type
7.3.3.2.6. By Application
7.3.3.2.7. By End User
7.3.4. Italy Multicancer Screening Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value & Volume
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Test Type
7.3.4.2.2. By Technology
7.3.4.2.3. By Sample
7.3.4.2.4. By Method
7.3.4.2.5. By Cancer Type
7.3.4.2.6. By Application
7.3.4.2.7. By End User
7.3.5. Spain Multicancer Screening Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value & Volume
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Test Type
7.3.5.2.2. By Technology
7.3.5.2.3. By Sample
7.3.5.2.4. By Method
7.3.5.2.5. By Cancer Type
7.3.5.2.6. By Application
7.3.5.2.7. By End User
8. ASIA-PACIFIC MULTICANCER SCREENING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Technology
8.2.3. By Sample
8.2.4. By Method
8.2.5. By Cancer Type
8.2.6. By Application
8.2.7. By End User
8.2.8. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Multicancer Screening Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value & Volume
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By Technology
8.3.1.2.3. By Sample
8.3.1.2.4. By Method
8.3.1.2.5. By Cancer Type
8.3.1.2.6. By Application
8.3.1.2.7. By End User
8.3.2. India Multicancer Screening Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value & Volume
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By Technology
8.3.2.2.3. By Sample
8.3.2.2.4. By Method
8.3.2.2.5. By Cancer Type
8.3.2.2.6. By Application
8.3.2.2.7. By End User
8.3.3. South Korea Multicancer Screening Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value & Volume
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By Technology
8.3.3.2.3. By Sample
8.3.3.2.4. By Method
8.3.3.2.5. By Cancer Type
8.3.3.2.6. By Application
8.3.3.2.7. By End User
8.3.4. Japan Multicancer Screening Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value & Volume
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type
8.3.4.2.2. By Technology
8.3.4.2.3. By Sample
8.3.4.2.4. By Method
8.3.4.2.5. By Cancer Type
8.3.4.2.6. By Application
8.3.4.2.7. By End User
8.3.5. Australia Multicancer Screening Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value & Volume
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type
8.3.5.2.2. By Technology
8.3.5.2.3. By Sample
8.3.5.2.4. By Method
8.3.5.2.5. By Cancer Type
8.3.5.2.6. By Application
8.3.5.2.7. By End User
9. SOUTH AMERICA MULTICANCER SCREENING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Technology
9.2.3. By Sample
9.2.4. By Method
9.2.5. By Cancer Type
9.2.6. By Application
9.2.7. By End User
9.2.8. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Multicancer Screening Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value & Volume
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By Technology
9.3.1.2.3. By Sample
9.3.1.2.4. By Method
9.3.1.2.5. By Cancer Type
9.3.1.2.6. By Application
9.3.1.2.7. By End User
9.3.2. Argentina Multicancer Screening Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value & Volume
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By Technology
9.3.2.2.3. By Sample
9.3.2.2.4. By Method
9.3.2.2.5. By Cancer Type
9.3.2.2.6. By Application
9.3.2.2.7. By End User
9.3.3. Colombia Multicancer Screening Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value & Volume
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By Technology
9.3.3.2.3. By Sample
9.3.3.2.4. By Method
9.3.3.2.5. By Cancer Type
9.3.3.2.6. By Application
9.3.3.2.7. By End User
10. MIDDLE EAST AND AFRICA MULTICANCER SCREENING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Test Type
10.2.2. By Technology
10.2.3. By Sample
10.2.4. By Method
10.2.5. By Cancer Type
10.2.6. By Application
10.2.7. By End User
10.2.8. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Multicancer Screening Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value & Volume
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type
10.3.1.2.2. By Technology
10.3.1.2.3. By Sample
10.3.1.2.4. By Method
10.3.1.2.5. By Cancer Type
10.3.1.2.6. By Application
10.3.1.2.7. By End User
10.3.2. Saudi Arabia Multicancer Screening Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value & Volume
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Test Type
10.3.2.2.2. By Technology
10.3.2.2.3. By Sample
10.3.2.2.4. By Method
10.3.2.2.5. By Cancer Type
10.3.2.2.6. By Application
10.3.2.2.7. By End User
10.3.3. UAE Multicancer Screening Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value & Volume
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Test Type
10.3.3.2.2. By Technology
10.3.3.2.3. By Sample
10.3.3.2.4. By Method
10.3.3.2.5. By Cancer Type
10.3.3.2.6. By Application
10.3.3.2.7. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
13. PESTLE ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (In case of listed companies)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. Agilent Technologies, Inc.
15.6.2. Atara Biotherapeutics, Inc.
15.6.3. Burning Rock Biotech Limited
15.6.4. Exact Sciences Corp.
15.6.5. F. Hoffmann-La Roche Ltd.
15.6.6. Fulgent Genetics, Inc.
15.6.7. Genecast Biotechnology Co., Ltd.
15.6.8. Guardant Health, Inc.
15.6.9. Illumina, Inc. (GRAIL, LLC.)
15.6.10. Konica Minolta, Inc. (Ambry Genetics.)
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL MULTICANCER SCREENING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value & Volume
5.2. Market Share & Forecast
5.2.1. By Test Type (Laboratory Developed Tests (LDTs), In-Vitro Diagnostics (IVDs))
5.2.2. By Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), Fluorescence In-Situ Hybridization (FISH), and Other Technologies)
5.2.3. By Sample (Tissue, Blood, Saliva and Buccal Swab, and Others)
5.2.4. By Method (DNA, RNA, and Proteins)
5.2.5. By Cancer Type (Breast and Gynecologic, Gastrointestinal, Endocrine, Genitourinary, Skin, Brain/Nervous System, Sarcoma, Hematological Malignancies, Lung, Head and Neck, and Other Cancer Types)
5.2.6. By Application (Clinical, Research)
5.2.7. By End User (Hospitals, Diagnostic and Clinical Laboratories, Academic Research Institutions, and Other End Users)
5.2.8. By Region
5.2.9. By Company (2022)
5.3. Product Market Map
6. NORTH AMERICA MULTICANCER SCREENING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value & Volume
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Technology
6.2.3. By Sample
6.2.4. By Method
6.2.5. By Cancer Type
6.2.6. By Application
6.2.7. By End User
6.2.8. By Country
6.3. North America: Country Analysis
6.3.1. United States Multicancer Screening Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value & Volume
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By Technology
6.3.1.2.3. By Sample
6.3.1.2.4. By Method
6.3.1.2.5. By Cancer Type
6.3.1.2.6. By Application
6.3.1.2.7. By End User
6.3.2. Mexico Multicancer Screening Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value & Volume
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type
6.3.2.2.2. By Technology
6.3.2.2.3. By Sample
6.3.2.2.4. By Method
6.3.2.2.5. By Cancer Type
6.3.2.2.6. By Application
6.3.2.2.7. By End User
6.3.3. Canada Multicancer Screening Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value & Volume
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type
6.3.3.2.2. By Technology
6.3.3.2.3. By Sample
6.3.3.2.4. By Method
6.3.3.2.5. By Cancer Type
6.3.3.2.6. By Application
6.3.3.2.7. By End User
7. EUROPE MULTICANCER SCREENING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value & Volume
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Technology
7.2.3. By Sample
7.2.4. By Method
7.2.5. By Cancer Type
7.2.6. By Application
7.2.7. By End User
7.2.8. By Country
7.3 Europe: Country Analysis
7.3.1. France Multicancer Screening Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value & Volume
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By Technology
7.3.1.2.3. By Sample
7.3.1.2.4. By Method
7.3.1.2.5. By Cancer Type
7.3.1.2.6. By Application
7.3.1.2.7. By End User
7.3.2. Germany Multicancer Screening Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value & Volume
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type
7.3.2.2.2. By Technology
7.3.2.2.3. By Sample
7.3.2.2.4. By Method
7.3.2.2.5. By Cancer Type
7.3.2.2.6. By Application
7.3.2.2.7. By End User
7.3.3. United Kingdom Multicancer Screening Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value & Volume
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Test Type
7.3.3.2.2. By Technology
7.3.3.2.3. By Sample
7.3.3.2.4. By Method
7.3.3.2.5. By Cancer Type
7.3.3.2.6. By Application
7.3.3.2.7. By End User
7.3.4. Italy Multicancer Screening Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value & Volume
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Test Type
7.3.4.2.2. By Technology
7.3.4.2.3. By Sample
7.3.4.2.4. By Method
7.3.4.2.5. By Cancer Type
7.3.4.2.6. By Application
7.3.4.2.7. By End User
7.3.5. Spain Multicancer Screening Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value & Volume
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Test Type
7.3.5.2.2. By Technology
7.3.5.2.3. By Sample
7.3.5.2.4. By Method
7.3.5.2.5. By Cancer Type
7.3.5.2.6. By Application
7.3.5.2.7. By End User
8. ASIA-PACIFIC MULTICANCER SCREENING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value & Volume
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Technology
8.2.3. By Sample
8.2.4. By Method
8.2.5. By Cancer Type
8.2.6. By Application
8.2.7. By End User
8.2.8. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Multicancer Screening Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value & Volume
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By Technology
8.3.1.2.3. By Sample
8.3.1.2.4. By Method
8.3.1.2.5. By Cancer Type
8.3.1.2.6. By Application
8.3.1.2.7. By End User
8.3.2. India Multicancer Screening Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value & Volume
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By Technology
8.3.2.2.3. By Sample
8.3.2.2.4. By Method
8.3.2.2.5. By Cancer Type
8.3.2.2.6. By Application
8.3.2.2.7. By End User
8.3.3. South Korea Multicancer Screening Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value & Volume
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By Technology
8.3.3.2.3. By Sample
8.3.3.2.4. By Method
8.3.3.2.5. By Cancer Type
8.3.3.2.6. By Application
8.3.3.2.7. By End User
8.3.4. Japan Multicancer Screening Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value & Volume
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type
8.3.4.2.2. By Technology
8.3.4.2.3. By Sample
8.3.4.2.4. By Method
8.3.4.2.5. By Cancer Type
8.3.4.2.6. By Application
8.3.4.2.7. By End User
8.3.5. Australia Multicancer Screening Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value & Volume
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type
8.3.5.2.2. By Technology
8.3.5.2.3. By Sample
8.3.5.2.4. By Method
8.3.5.2.5. By Cancer Type
8.3.5.2.6. By Application
8.3.5.2.7. By End User
9. SOUTH AMERICA MULTICANCER SCREENING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value & Volume
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Technology
9.2.3. By Sample
9.2.4. By Method
9.2.5. By Cancer Type
9.2.6. By Application
9.2.7. By End User
9.2.8. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Multicancer Screening Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value & Volume
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By Technology
9.3.1.2.3. By Sample
9.3.1.2.4. By Method
9.3.1.2.5. By Cancer Type
9.3.1.2.6. By Application
9.3.1.2.7. By End User
9.3.2. Argentina Multicancer Screening Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value & Volume
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By Technology
9.3.2.2.3. By Sample
9.3.2.2.4. By Method
9.3.2.2.5. By Cancer Type
9.3.2.2.6. By Application
9.3.2.2.7. By End User
9.3.3. Colombia Multicancer Screening Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value & Volume
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By Technology
9.3.3.2.3. By Sample
9.3.3.2.4. By Method
9.3.3.2.5. By Cancer Type
9.3.3.2.6. By Application
9.3.3.2.7. By End User
10. MIDDLE EAST AND AFRICA MULTICANCER SCREENING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value & Volume
10.2. Market Share & Forecast
10.2.1. By Test Type
10.2.2. By Technology
10.2.3. By Sample
10.2.4. By Method
10.2.5. By Cancer Type
10.2.6. By Application
10.2.7. By End User
10.2.8. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Multicancer Screening Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value & Volume
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type
10.3.1.2.2. By Technology
10.3.1.2.3. By Sample
10.3.1.2.4. By Method
10.3.1.2.5. By Cancer Type
10.3.1.2.6. By Application
10.3.1.2.7. By End User
10.3.2. Saudi Arabia Multicancer Screening Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value & Volume
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Test Type
10.3.2.2.2. By Technology
10.3.2.2.3. By Sample
10.3.2.2.4. By Method
10.3.2.2.5. By Cancer Type
10.3.2.2.6. By Application
10.3.2.2.7. By End User
10.3.3. UAE Multicancer Screening Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value & Volume
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Test Type
10.3.3.2.2. By Technology
10.3.3.2.3. By Sample
10.3.3.2.4. By Method
10.3.3.2.5. By Cancer Type
10.3.3.2.6. By Application
10.3.3.2.7. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
13. PESTLE ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Product
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Company Snapshot
15.3. Products & Services
15.4. Financials (In case of listed companies)
15.5. Recent Developments
15.6. SWOT Analysis
15.6.1. Agilent Technologies, Inc.
15.6.2. Atara Biotherapeutics, Inc.
15.6.3. Burning Rock Biotech Limited
15.6.4. Exact Sciences Corp.
15.6.5. F. Hoffmann-La Roche Ltd.
15.6.6. Fulgent Genetics, Inc.
15.6.7. Genecast Biotechnology Co., Ltd.
15.6.8. Guardant Health, Inc.
15.6.9. Illumina, Inc. (GRAIL, LLC.)
15.6.10. Konica Minolta, Inc. (Ambry Genetics.)
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
